N-acetyl-D-glucosamine kinase (NAGK)

N-acetyl-D-glucosamine kinase (NAGK) is an enzyme that catalyzes the phosphorylation of N-acetylglucosamine (GlcNAc) to N-acetylglucosamine-6-phosphate (GlcNAc-6P), a critical step in the amino sugar salvage pathway[1][2][3]. In mammals, NAGK provides GlcNAc-6P for the synthesis of UDP-GlcNAc, a pivotal precursor for protein glycosylation, glycolipids, and glycosaminoglycans[2][3]. NAGK is ubiquitously expressed, with structural studies showing it forms homodimers and belongs to the ROK family of sugar kinases[1][2]. In neuronal cells, NAGK also has a non-enzymatic structural function essential for dendritic growth, distinct from its kinase activity[2]. In bacteria, NAGK is vital for cell wall recycling and biosynthesis, making it a candidate antibacterial drug target[1]. Regulation of NAGK includes phosphorylation and pyrophosphorylation, which can inhibit its enzymatic function and modulate its protein interaction network[4]. There are currently no known approved drugs or clinical biomarkers directly targeting NAGK in humans, but its essential role in bacterial and mammalian GlcNAc metabolism underscores its biological importance[1][2][3][4].

Other names

N-acetylglucosamine kinaseGlcNAc kinaseGNKMuramyl dipeptide kinaseN-acetyl-D-mannosamine kinaseglcNAc kinaseepididymis secretory sperm binding proteinHSA242910

No drugs directly described; however, small molecule inhibitors could theoretically act as enzyme inhibitors by blocking ATP or GlcNAc binding